BMS to Use Foundation Medicine Platform in Immuno-Oncology Partnership

Bristol-Myers Squibb (BMS) will use Foundation Medicine’s genomic profiling and molecular information solutions to identify predictive biomarkers in patients enrolled in clinical trials assessing the pharma giant’s cancer immunotherapies, the companies said today.

Spotlight

Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Spotlight

Resources